TABLE II.
De novo patients | OS LR | EFS LR | DFS LR | OS IR | EFS IR | DFS IR |
---|---|---|---|---|---|---|
CCG-2961 post-susp [9] | 72 ± 12% (n = 60) | 60 ± 13% (n = 60) | 62 ± 14% (n = 47) | 51 ± 7% (n = 190) | 39 ± 7% (n = 190) | 48 ± 9% (n = 125) |
COG AAML03P1 [3] | 83 ± 9% (n = 78) | 67 ± 11% (n = 78) | 66 ± 11% (n = 70) | 62 ± 7% (n = 225) | 49 ± 7% (n = 225) | 57 ± 8% (n = 171) |